Wegovy's Real-World Effectiveness and Safety in Korean Patients with Obesity to be Assessed Over 52 Weeks

Obesity is a chronic disease linked to numerous comorbidities, posing significant public health challenges globally. Current management strategies, including diet, exercise, and traditional pharmacotherapy, often struggle to achieve and maintain substantial long-term weight loss, leading to a critical gap in effective treatment options. GLP-1 receptor agonists, such as semaglutide, have emerged as powerful new therapeutic agents by mimicking natural incretin hormones, thereby enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety. This mechanism leads to significant weight reduction and improved metabolic health, making it vital to assess their real-world efficacy and safety in diverse patient populations like those in Korea.

This is a multi-center, prospective, non-interventional, single-arm, 52-week post-marketing observational study conducted in Korea. The study will enroll Korean patients diagnosed with obesity who are initiating or continuing treatment with Wegovy (semaglutide) as prescribed by their attending physician, reflecting normal clinical practice. The primary objective is to investigate the change in body weight from baseline and other relevant clinical characteristics related to body weight, such as BMI, waist circumference, and metabolic parameters, over the study duration. Participants will be followed for approximately 52 weeks to gather real-world data on the effectiveness and safety of semaglutide in this specific demographic.